Related Experiment Videos
Beta-blocker use and COPD mortality: a systematic review and meta-analysis
Mahyar Etminan1, Siavash Jafari, Bruce Carleton
1Therapeutic Evaluation Unit, British Columbia Provincial Health Services Authority, Vancouver, Canada. metminan@popi.ubc.ca
BMC Pulmonary Medicine
|September 6, 2012
Summary
Beta-blocker use in chronic obstructive pulmonary disease (COPD) patients may reduce mortality. This systematic review found a protective effect, but further randomized controlled trials are needed to confirm these findings for COPD patients.
Area of Science:
- Cardiology
- Pulmonology
- Pharmacology
Background:
- Beta-blockers offer cardiovascular benefits but their use in COPD patients is debated.
- Existing research lacks systematic reviews on beta-blocker impact on COPD mortality.
Purpose of the Study:
- To systematically review and analyze the association between beta-blocker use and all-cause mortality in patients with COPD.
Main Methods:
- Systematic search of MEDLINE, EMBASE, and Cochrane Library for relevant clinical studies.
- Pooled risk ratios using random-effects models to estimate overall mortality risk.
- Publication bias assessed using funnel plots.
Main Results:
- Nine retrospective cohort studies were included in the analysis.
- Beta-blocker use was associated with a reduced risk of COPD-related mortality (pooled RR: 0.69; 95% CI: 0.62-0.78).
- Significant heterogeneity was observed (I2=82%).
Conclusions:
- Findings suggest a potential protective effect of beta-blockers against all-cause mortality in COPD patients.
- Observational nature of studies necessitates caution due to potential confounding factors.
- Randomized controlled trials are recommended to validate the benefits of beta-blocker therapy in COPD.
Related Concept Videos
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:28Antihypertensive Drugs: Types of β-Blockers
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...